从TGN1412试验中吸取教训。
Learning from the TGN1412 trial.
作者信息
Goodyear Michael
出版信息
BMJ. 2006 Mar 25;332(7543):677-8. doi: 10.1136/bmj.38797.635012.47. Epub 2006 Mar 22.
Abstract
This experience should foster an open culture in medical research
摘要
这种经历应在医学研究中培育一种开放的文化。
相似文献
1
Learning from the TGN1412 trial.从TGN1412试验中吸取教训。
BMJ. 2006 Mar 25;332(7543):677-8. doi: 10.1136/bmj.38797.635012.47. Epub 2006 Mar 22.
2
Severe adverse reactions prompt call for trial design changes.严重不良反应促使人们呼吁改变试验设计。
BMJ. 2006 Mar 25;332(7543):683. doi: 10.1136/bmj.332.7543.683.
3
TeGenero fiasco prompts regulatory rethink.特杰内罗事件促使监管机构重新思考。
Nat Biotechnol. 2006 May;24(5):475-6. doi: 10.1038/nbt0506-475.
4
[Why has the drug trial at Northwick Park Hospital turned out to a disaster?].[为何诺斯威克公园医院的药物试验会以灾难告终？]
Lakartidningen. 2006;103(15-16):1169-70.
5
Does the TGN1412 trial disaster have lessons for clinical trials in India?TGN1412试验灾难对印度的临床试验有何教训？
Natl Med J India. 2006 Sep-Oct;19(5):283-6.
6
CD28 superagonists: what makes the difference in humans?CD28超激动剂：在人类身上产生差异的原因是什么？
Immunity. 2008 May;28(5):591-5. doi: 10.1016/j.immuni.2008.04.003.
7
The sex kitten of bioethics? Research ethics comes of age.生物伦理学的性感小猫？研究伦理走向成熟。
Hastings Cent Rep. 2008 Sep-Oct;38(5):5.
8
TGN1412: the catalyst for change?TGN1412：变革的催化剂？
Altern Lab Anim. 2006 Aug;34(4):369-71.
9
Cytokine storm and an anti-CD28 monoclonal antibody.细胞因子风暴与一种抗CD28单克隆抗体。
N Engl J Med. 2006 Dec 14;355(24):2592-3; author reply 2593-4. doi: 10.1056/NEJMc062750.
10
Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.德国单克隆抗体I期临床试验的安全性——TGN1412灾难后审视监管要求
Int J Clin Pharmacol Ther. 2007 Jan;45(1):1-9. doi: 10.5414/cpp45001.
引用本文的文献
1
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.替雷利珠单抗诱导的细胞因子释放综合征：首例病例报告及文献综述
Immunotherapy. 2024;16(18-19):1113-1122. doi: 10.1080/1750743X.2024.2422814. Epub 2024 Nov 21.
2
Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?实践和政策是否应该修订，以便向人类挑战研究参与者提供与风险相称的报酬？
J Med Ethics. 2020 Dec;46(12):835-836. doi: 10.1136/medethics-2020-106900. Epub 2020 Nov 5.
3
Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations.制药行业、支持动物测试游说团体和动物福利组织最近努力阐明动物药物测试的科学有效性。
BMC Med Ethics. 2019 Mar 1;20(1):16. doi: 10.1186/s12910-019-0352-3.
4
Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs.药物、器械与美国食品药品监督管理局：第一部分：药物审批流程概述
JACC Basic Transl Sci. 2016 Apr 25;1(3):170-179. doi: 10.1016/j.jacbts.2016.03.002. eCollection 2016 Apr.
5
Validation of a free fall acrobatics intervention protocol to reduce neck loads during parachute opening shock.一种自由落体杂技干预方案在降落伞开伞冲击期间减轻颈部负荷的验证。
BMJ Open Sport Exerc Med. 2015 Nov 2;1(1). doi: 10.1136/bmjsem-2015-000045. eCollection 2015.
6
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.下一代蛋白质治疗药物的药代动力学和药效学考量
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):553-71. doi: 10.1007/s10928-015-9447-8. Epub 2015 Sep 15.
7
Compensation for research related injury.对研究相关损伤的补偿。
Perspect Clin Res. 2013 Jan;4(1):61-9. doi: 10.4103/2229-3485.106392.
8
Systematic archiving and access to health research data: rationale, current status and way forward.系统归档和获取健康研究数据：基本原理、当前状况和未来发展方向。
Bull World Health Organ. 2012 Dec 1;90(12):932-9. doi: 10.2471/BLT.12.105908. Epub 2012 Oct 10.
9
Cytokines in radiobiological responses: a review.细胞因子在放射生物学反应中的作用：综述。
Radiat Res. 2012 Dec;178(6):505-23. doi: 10.1667/RR3031.1. Epub 2012 Oct 29.
10
Paternalism and utilitarianism in research with human participants.涉及人类受试者研究中的家长主义与功利主义。
Health Care Anal. 2015 Mar;23(1):19-31. doi: 10.1007/s10728-012-0233-0.
本文引用的文献
1
Is society losing control of the medical research agenda?社会正在失去对医学研究议程的控制吗？
BMJ. 2006 May 6;332(7549):1063-4. doi: 10.1136/bmj.38771.471563.80. Epub 2006 Mar 17.
2
CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.CD28超激动剂通过优先激活CD4+CD25+调节性T细胞来抑制自身免疫。
Autoimmun Rev. 2006 Jan;5(1):40-5. doi: 10.1016/j.autrev.2005.06.001. Epub 2005 Jul 7.
3
The contract research organization and the commercialization of scientific research.合同研究组织与科研成果商业化
Soc Stud Sci. 2005 Aug;35(4):503-48. doi: 10.1177/0306312705052103.
4
Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).健康相关干预措施人体试验方案信息及结果的国际注册原则：渥太华声明（第1部分）
BMJ. 2005 Apr 23;330(7497):956-8. doi: 10.1136/bmj.330.7497.956.
5
Registering clinical trials.临床试验注册
JAMA. 2003 Jul 23;290(4):516-23. doi: 10.1001/jama.290.4.516.
6
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression.T淋巴细胞抗原CD28的小鼠同源物。分子克隆与细胞表面表达。
J Immunol. 1990 Apr 15;144(8):3201-10.
Zotero 插件